TIGIT and cancer: However, anti-PD-L1 antibody showed no enhancement of CTL activity in the presence of mesenchymal cancer cells, while the impaired CTL activity was largely restored by anti-CTLA-4 and anti-TIGIT antibodies (Fig. 3f, h).